Homepage
Author:
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
Posted Date:
May 17, 2026
Caris Life Sciences Reports First Quarter 2026 Financial Results
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
May 17, 2026
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
May 5, 2026
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
May 4, 2026
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 29, 2026
Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 24, 2026
Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 20, 2026
Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 17, 2026
Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 15, 2026
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 8, 2026
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World’s First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
CARIS MPI, INC., d/b/a CARIS LIFE SCIENCES
April 2, 2026
1
2
3
Next
